1011797-06-0

Basic information

• Product Name: N-[3-(5-amino-1-methyl-6-oxo-1,6-dihydro-pyridin-3-yl)-2-methyl-phenyl]-4-tert-butyl-benzamide
• Synonyms: N-[3-(5-amino-1-methyl-6-oxo-1,6-dihydro-pyridin-3-yl)-2-methyl-phenyl]-4-tert-butyl-benzamide
• CAS NO: 1011797-06-0
• Molecular Weight: 389.497
• Mol File: 1011797-06-0.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: N-[3-(5-amino-1-methyl-6-oxo-1,6-dihydro-pyridin-3-yl)-2-methyl-phenyl]-4-tert-butyl-benzamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-[3-(5-amino-1-methyl-6-oxo-1,6-dihydro-pyridin-3-yl)-2-methyl-phenyl]-4-tert-butyl-benzamide(1011797-06-0)
• EPA Substance Registry System: N-[3-(5-amino-1-methyl-6-oxo-1,6-dihydro-pyridin-3-yl)-2-methyl-phenyl]-4-tert-butyl-benzamide(1011797-06-0)

Safety Data

• Hazardous Substances Data: 1011797-06-0(Hazardous Substances Data)

Upstream product

• 910543-72-5 3-amino-5-bromo-1-methyl-2H-pyridin-2-one 
• 910235-65-3 4-tert-butyl-N-[2-methyl-3-(4,4,5,5-tetramethyl-[1,2,3]dioxaborolan-2-yl)-phenyl]-benzamide 

Downstream Products

• 1147529-74-5 4-tert-butyl-N-{2-methyl-3-[1-methyl-5-(3-methyl-ureido)-6-oxo-1,6-dihydro-pyridin-3-yl]-phenyl}-benzamide 
• 1013115-68-8 4-tert-butyl-N-(2-methyl-3-(1-methyl-5-(6-morpholinopyridazin-3-ylamino)-6-oxo-1,6-dihydropyridin-3-yl)phenyl)benzamide 

Relevant articles and documents

BTK protein kinase inhibitors

This application discloses pyridine and pyrimidine compounds according to formula I wherein R1, R2, R3, R4, R5, X1 and A are as described herein which inhibit Btk. The compounds disclosed herein are useful to modulate the activity of Btk and treat diseases associated with excessive Btk activity. The compounds are further useful to treat inflammatory and auto immune diseases associated with aberrant B-cell proliferation such as rheumatoid arthritis. Also disclosed are compositions containing compounds of formula I and at least one carrier, diluent or excipient.

Certain Substituted Amides, Method of Making, and Method of Use Thereof

At least one chemical entity chosen from compounds of Formula 1 and pharmaceutically acceptable salts, solvates, chelates, non-covalent complexes, prodrugs, and mixtures thereof is described herein. Pharmaceutical compositions comprising at least one chemical entity of the invention, together with at least one pharmaceutically acceptable vehicle chosen from carriers adjuvants, and excipients, are described. Methods of treating patients suffering from certain diseases responsive to inhibition of Btk activity and/or B-cell activity are described. Methods for determining the presence of Btk in a sample are described.